top of page

Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma

  • blonca9
  • Apr 29, 2024
  • 1 min read

He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over previous attempts of using CAR-T against brain cancers.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page